Meeting
2021 ASCO Annual Meeting
Clinical trial in progress: Phase II trial of defactinib (VS-6063) combined with VS-6766 (CH5126766) in patients with metastatic uveal melanoma.
Authors
Rino S. Seedor
Fox Chase Cancer Center, Philadelphia, PA
Rino S. Seedor , Marlana Orloff , J. Silvio Gutkind , Andrew E. Aplin , Mizue Terai , Erin Sharpe-Mills , Haley Klose , Michael J. Mastrangelo , Takami Sato
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04720417
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS9588)
DOI
10.1200/JCO.2021.39.15_suppl.TPS9588
Abstract #
TPS9588
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase II study of ERK inhibition by ulixertinib (BVD-523) in metastatic uveal melanoma.
First Author: Elizabeth Iannotti Buchbinder
Poster
2023 ASCO Annual Meeting
Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).
First Author: Susana N. Banerjee
Poster
2022 ASCO Annual Meeting
ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of VS-6766 (RAF/MEK clamp) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC).
First Author: Susana N. Banerjee
Poster
2021 ASCO Annual Meeting
ENGOT-ov60/GOG3052/RAMP 201: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC).
First Author: Susana N. Banerjee